biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Microglia’s Role in MS and Other Neurodegenerative Diseases

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Aug 21, 2021 12:13pm

124 Views

Post# 33745029

RE:RE:Microglia’s Role in MS and Other Neurodegenerative Diseases

Interesting video, hugenews111. I really liked FSD Pharma Inc CEO Anthony Durkacz's comment about it being better having institutions in late and buying from retail than having institutions in early and selling to retail.

About using a protein (PEA) to treat neuroinflammation, even if it uses the CBD path to the brain, it's interesting but FSD, as he admits, has only the one program and it's a long way from prime time. Well-funded, it seems, however.

And I'd want to hear from a capable scientist than from the financier/promoter.

jd

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing